Vânia TM Hungria

Multiple myeloma with t(11;14): unique biology and evolving landscape.

Susan Bal, Shaji Kumar, Rafaël Fonseca et al. · PubMed · 2022 · 40 citations · Full text

Hematological Malignancy, Medicine, Malignant Blood Disorder +10

Efficacy and safety of the randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients (pts) with relapsed or refractory multiple myeloma (RRMM): COLUMBA.

María‐Victoria Mateos, Hareth Nahi, Wojciech Legieć et al. · Journal of Clinical Oncology · 2019 · 24 citations

Median Duration, Pharmacotherapy, Immunotherapy +17

A phase 3, open-label, randomized study to evaluate the efficacy and safety of single-agent belantamab mafodotin (belamaf) compared to pomalidomide plus low-dose dexamethasone (Pd) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): DREAMM-3.

Katja Weisel, Vânia TM Hungria, Atanas Radinoff et al. · Journal of Clinical Oncology · 2023 · 12 citations

Immunology, Pharmacotherapy, Immunotherapeutics +21